[PDF] Top 20 Manual de Mantenimiento,Operacion y Seguridad en Español

... other outcomes (in particular, weight and length of the baby, pre-term delivery, cesarean delivery) were compared between the exposed and not-exposed ...The study was approved by the ethic committee of the ... See full document

... MS patients (demographic data, education, smoke, alcohol in- take, family history of malformations or other diseases, data regarding MS history and therapy), a section related to their partners’ pregnancy ... See full document

... In patients with relapsing remitting multiple sclerosis (RRMS) treatment with disease modifying drugs (DMDs) is associated with a decrease in the frequency and sever- ity of relapses [1], and a ... See full document

... treatment-naive patients showed a mean increase in LMS-QoL score of about ...MS patients. In general, changes of 10% to 15% in clinical outcomes may be considered ...Thus, after one year 4 out ... See full document

... COPTIMIZE study was designed to monitor clin- ical outcomes after converting from failing or ineffective DMT therapy for RRMS to glatiramer acetate (GA) in a prospective ...in ... See full document

... of patients already indi- cated that they felt confident with the BETACONNECT® compared with their previous way of injection and that they preferred it to their previous ...survey-based study conducted on ... See full document

... Care provided by the following disciplines was assessed: neurologist, nurse, psychologist, pharmacist, rehabilitation doctor, general practitioner, other medical specialists, occu- pational therapist, physiotherapist, ... See full document

... Multiple sclerosis (MS) is a chronic inflammatory demye- linating disease of the central nervous system, for which no definite cure is ...Most patients start with a relapsing-remitting (RR) phase ... See full document

... increased after one year of treatment, suggesting differ- ent immunological mechanisms ...of patients discon- tinuing NAT due to safety issues related to this therapy, particularly regarding PML ...short ... See full document

... A queste sono state aggiunte ulteriori correlazioni tra le sottoscale della scala salute fisica e mentale (Tab. II) e il punteggio totale della scala MFIS, per individuare qua- li dell[r] ... See full document

... out glatiramer acetate is the best option only in patients with similar health ef- fects, but it could not be the best option in patients with lower health ... See full document

... Taken together, these data led to the hypothesis that GA acts as an APL in vivo, leading to alterations of responses to myelin antigens by cytokine deviation of myelin-specific T cells and bystander suppression mediated ... See full document

... assess fetal cardiac func- ...used, study limitations as cross sectional study design, low number of included fetuses and low frame rates in the heart cycle clips ...the fetal heart as it is ... See full document

... At study entry, women will be interviewed or have data abstracted about their medical, vaccination, and preg- nancy ...during pregnancy, at delivery, and 6-weeks (+/− 2 weeks) post-partum, women will have a ... See full document

... the study of Wandinger [11] et ...the study of Wandinger et ...of multiple sclerosis (MS). The study of Wandinger et ...MS patients for EBV compared with control ... See full document

... In Nigeria, utilization of maternal healthcare services has remained poor. A national survey in 2013 showed that less than two-thirds of women who had a live birth in the five years preceding the survey received ANC from ... See full document

... second study, 116 patients being treated with an IFN were randomized to receive a daily dose of either teriflunomide 7 mg (n = 37), teriflunomide 14 mg (n = 38), or placebo (n = 41), concurrently over 24 ... See full document

... remitting multiple sclerosis in the United Kingdom: interferon beta-1a (6 MIU/week; Avonex, Biogen), interferon beta-1b (8 MIU/week; Betaferon, Schering Health), glatiramer acetate (20 ... See full document

... Background: Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous ...system. Glatiramer acetate (GA) is a commonly used immunomodulating ...in patients ... See full document

... Of note, we did not observe statistically significant changes in the MBP-specific proliferative responses in these patients during the treatment course, although individual patients showed mild variation. ... See full document